MA48461A - Excipients pour réduire la viscosité de formulations d'anticorps et compositions de formulation - Google Patents

Excipients pour réduire la viscosité de formulations d'anticorps et compositions de formulation

Info

Publication number
MA48461A
MA48461A MA048461A MA48461A MA48461A MA 48461 A MA48461 A MA 48461A MA 048461 A MA048461 A MA 048461A MA 48461 A MA48461 A MA 48461A MA 48461 A MA48461 A MA 48461A
Authority
MA
Morocco
Prior art keywords
excipients
viscosity
reduce
antibody formulations
formulation compositions
Prior art date
Application number
MA048461A
Other languages
English (en)
Inventor
Robert Matthew Fesinmeyer
Jian Hua Gu
Rulin Qian
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA48461A publication Critical patent/MA48461A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
MA048461A 2017-04-28 2018-04-24 Excipients pour réduire la viscosité de formulations d'anticorps et compositions de formulation MA48461A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762492049P 2017-04-28 2017-04-28

Publications (1)

Publication Number Publication Date
MA48461A true MA48461A (fr) 2020-03-04

Family

ID=62148500

Family Applications (1)

Application Number Title Priority Date Filing Date
MA048461A MA48461A (fr) 2017-04-28 2018-04-24 Excipients pour réduire la viscosité de formulations d'anticorps et compositions de formulation

Country Status (4)

Country Link
US (2) US12257343B2 (fr)
EP (1) EP3615065A1 (fr)
MA (1) MA48461A (fr)
WO (1) WO2018200533A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109439536A (zh) * 2017-08-18 2019-03-08 黄国仁 饮用水细菌快速培养装置及菌落总数快速检测系统
CN112218877B (zh) 2018-08-27 2025-07-25 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
AR118536A1 (es) * 2019-04-01 2021-10-20 Genentech Inc Composiciones y métodos para estabilizar formulaciones que contienen proteína
MX2022001805A (es) * 2019-08-12 2022-06-08 Amgen Inc Formulaciones de anticuerpos anti-esclerostina.
IL293450A (en) 2019-12-03 2022-07-01 Evotec Int Gmbh Interferon-associated antigen binding proteins and uses thereof
KR20220140772A (ko) * 2020-02-13 2022-10-18 암젠 인크 인간 항-tslp 항체 제형 및 염증성 질환의 치료 방법
PE20230115A1 (es) * 2020-02-18 2023-01-27 Amgen Inc Formulaciones de anticuerpos anti-tslp humanos y metodos de uso de los mismos
BR112022026670A2 (pt) * 2020-07-13 2023-01-24 Merck Patent Gmbh Excipientes de redução da viscosidade e combinações dos mesmos para formulações de proteína altamente concentradas
WO2023140807A1 (fr) * 2022-01-19 2023-07-27 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Compositions pharmaceutiques de trastuzumab
US12110324B2 (en) 2022-07-22 2024-10-08 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)
WO2026003765A1 (fr) 2024-06-25 2026-01-02 Kiniksa Pharmaceuticals, Gmbh Formulations d'anticorps anti-récepteur 1 de l'interleukine 1

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (fr) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Récepteurs chimériques par liaison et expression de l'ADN
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
ES2087997T3 (es) 1990-01-12 1996-08-01 Cell Genesys Inc Generacion de anticuerpos xenogenicos.
WO2004039337A2 (fr) 2002-10-31 2004-05-13 Protein Design Labs, Inc. Formulations pharmaceutiques liquides stables d'anticorps ayant tendance a l'isomerisation
AU2003293543A1 (en) 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
ES2776657T3 (es) 2005-06-14 2020-07-31 Amgen Inc Formulaciones de proteínas autotamponantes
AU2007212147A1 (en) 2006-02-03 2007-08-16 Medimmune, Llc Protein formulations
CA2672902C (fr) 2006-12-21 2012-11-27 Amgen Inc. Formulations
EP2114451A2 (fr) 2007-01-09 2009-11-11 Wyeth a Corporation of the State of Delaware Préparations d'anticorps ant-il-13 et leurs utilisations
AU2008232903B9 (en) 2007-03-30 2013-09-05 Medimmune Llc Antibodies with decreased deamidation profiles
TWI505838B (zh) 2010-01-20 2015-11-01 中外製藥股份有限公司 Stabilized antibody solution containing
RU2012151500A (ru) * 2010-05-03 2014-06-10 Дженентек, Инк. Композиции и способы, пригодные для снижения вязкости белковосодержащих составов
EP2699265B1 (fr) * 2011-04-20 2019-10-16 Sandoz AG Formulations liquides pharmaceutiques stables de la protéine de fusion tnfr:fc
CN104023748B (zh) 2011-10-28 2018-03-02 诚信生物公司 含有氨基酸的蛋白质制剂
IL312865B2 (en) * 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
US20160074515A1 (en) 2014-06-20 2016-03-17 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
MX2017000527A (es) * 2014-07-14 2017-08-10 Amgen Inc Formulaciones de anticuerpos cristalinos.
MX388858B (es) 2014-10-23 2025-03-20 Amgen Inc Reducción de la viscosidad de formulaciones farmacéuticas
JOP20190255A1 (ar) * 2017-04-28 2019-10-27 Amgen Inc صيغ أجسام مضادة لـ rankl بشري، وطرق لاستخدامها

Also Published As

Publication number Publication date
US20250367115A1 (en) 2025-12-04
US12257343B2 (en) 2025-03-25
US20200352857A1 (en) 2020-11-12
WO2018200533A1 (fr) 2018-11-01
EP3615065A1 (fr) 2020-03-04

Similar Documents

Publication Publication Date Title
MA48461A (fr) Excipients pour réduire la viscosité de formulations d'anticorps et compositions de formulation
EP3618871A4 (fr) Formulations d'anticorps anti-lag3 etco-formulations d'anticorps anti-lag3 et d'anticorps anti-pd-1
MA49043A (fr) Formulation stable d'anticorps
EP3880688A4 (fr) Préparations et compositions d'oligosaccharides
EP3548000A4 (fr) Compositions pharmaceutiques d'atropine
MA56006A (fr) Formulations sous-cutanées d'anticorps her2
MA51796A (fr) Procédés et compositions pour l'administration de protéines thérapeutiques
EP3840730A4 (fr) Compositions pour l'administration d'agents thérapeutiques et leurs méthodes d'utilisation et leurs procédés de préparation
EP3256149A4 (fr) Formulations pour administration orale d'agents actifs
MA54052A (fr) Formulation d'anticorps
EP3496753A4 (fr) Formulation d'anticorps anti-pd-1
MX2022001146A (es) Formulaciones de anticuerpos anti-pvrig y sus usos.
EP3823978A4 (fr) Compositions d'anticorps anti-fcrn
EP3927729A4 (fr) Formulation d'anticorps thérapeutique
EP3381451A4 (fr) Composition pharmaceutique utilisée pour réduire la graisse localisée et utilisation de la composition pharmaceutique
MA54139A (fr) Formulation d'anticorps
EP3684369A4 (fr) Compositions d'anticorps a33 et leurs méthodes d'utilisation en radioimmunothérapie
IL281938A (en) Stable semaglutide compositions and uses thereof
MA53466A (fr) Formulation stable d'anticorps anti-osmr
EP3625262A4 (fr) Immunoconjugués anti-folr1 et combinaisons d'anticorps anti-pd-1
CL2019001053A1 (es) Formulaciones farmacéuticas y métodos para prepararlas.
EP3817750A4 (fr) Compositions d'associations de cannabidiol
EP3500291A4 (fr) Formulations pour l'administration par voie orale d'agents actifs
MA49524A (fr) Compositions d'antagoniste de nk-1 et méthodes destinées à être utilisées dans le traitement de la dépression
EP3394099A4 (fr) Formulations d'anticorps anti-il-10 modifiés